Lipoprotein-associated phospholipase A2: Role in atherosclerosis and utility as a cardiovascular biomarker

Expert Review of Cardiovascular Therapy

Volumn 8, Issue 3, 2010, Pages 425-438

  Toth, Peter P ^a,b   McCullough, Peter A ^c   Wegner, Michael S ^d   Colley, Kenneth J ^d  

^a Sterling Rock Falls Clinic ^*  (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c WILLIAM BEAUMONT HOSPITAL   (United States)

^d diaDexus Inc   (United States)

Author keywords

Atherosclerosis; Inflammation; Low density lipoprotein cholesterol; Lysophosphatidylcholine; Macrophage; Oxidized fatty acid; Phospholipase; Phospholipid

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ABCIXIMAB; ATORVASTATIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; DARAPLADIB; FIBRIC ACID DERIVATIVE; FISH OIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MYELOPEROXIDASE; NICOTINIC ACID; PLACEBO; ROSUVASTATIN;

ACUTE CORONARY SYNDROME; ARTERY DISEASE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DEATH; DISABILITY; DOSE RESPONSE; DRUG MECHANISM; ENZYME ACTIVITY; HEART INFARCTION; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; LIPID METABOLISM; PATHOPHYSIOLOGY; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; REVIEW; RISK ASSESSMENT; RISK REDUCTION; UNSTABLE ANGINA PECTORIS;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; FEMALE; HUMANS; INCIDENCE; MALE; PROGNOSIS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 77949465176     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.10.18     Document Type: Review

References (77)

1. Toth PP. Making a case for quantitative assessment of cardiovascular risk. J. Clin. Lipidol. 1(4), 234-241 (2007).
2. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107(3), 363-369 (2003).
3. Blake GJ, Dada N, Fox JC, Manson JE, Ridker PM. A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. J. Am. Coll. Cardiol. 38(5), 1302-1306 (2001).
4. Nicholls SJ, Hazen SL. Myeloperoxidase and cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 25(6), 1102-1111 (2005).
5. Libby P. What have we learned about the biology of atherosclerosis? The role of inflammation. Am. J. Cardiol. 88(7B), 3J-6J (2001).
6. Libby P. Act local, act global: inflammation and the multiplicity of 'vulnerable' coronary plaques. J. Am. Coll. Cardiol. 45(10), 1600-1602 (2005).
7. Davies MJ, Gordon JL, Gearing AJ et al. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. J. Pathol. 171(3), 223-229 (1993).
8. Tabas I. Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency. Arterioscler. Thromb. Vasc. Biol. 25(11), 2255-2264 (2005).
9. Tabas I, Williams KJ, Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 116(16), 1832-1844 (2007).
10. Ridker P, Bassuk S, Toth PP. C-reactive protein and risk of cardiovascular disease: evidence and clinical application. Curr. Atheroscler. Rep. 5(5), 341-349 (2003).
11. Brennan ML, Hazen SL. Emerging role of myeloperoxidase and oxidant stress markers in cardiovascular risk assessment. Curr. Opin. Lipidol. 14(4), 353-359 (2003).
12. Ballantyne CM, Hoogeveen RC, Bang H et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 109(7), 837-842 (2004).
13. Ballantyne CM, Hoogeveen RC, Bang H et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch. Intern. Med. 165(21), 2479-2484 (2005).
14. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89-95 (2001).
15. Hak AE, Stehouwer CD, Bots ML et al. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler. Thromb. Vasc. Biol. 19(8), 1986-1991 (1999).
16. Clyne B, Olshaker JS. The C-reactive protein. J. Emerg. Med. 17(6), 1019-1025 (1999).
17. Lau DC, Dillon B, Yan H, Szmitko PE, Verma S. Adipokines: molecular links between obesity and atherosclerosis. Am. J. Physiol. Heart Circ. Physiol. 288(5), H2031-H2041 (2005).
18. Lloyd-Jones DM, Liu K, Tian L, Greenland P. Assessment of C-reactive protein in risk prediction for cardiovascular disease. Ann. Intern. Med. 145(1), 35-42 (2006).
19. Selvin E, Paynter NP, Erlinger TP. The effect of weight loss on C-reactive protein: a systematic review. Arch. Intern. Med. 167(1), 31-39 (2007).
20. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N. Engl. J. Med. 359(18), 1897-1908 (2008).
21. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J. Clin. Invest. 111(12), 1805-1812 (2003).
22. Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359(21), 2195-2207 (2008).
23. Glynn RJ, Danielson E, Fonseca FA et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N. Engl. J. Med. 360(18), 1851-1861 (2009).
24. Everett BM, Glynn RJ, MacFadyen JG, Ridker PM. Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Circulation 121(1), 143-150 (2010).
25. Danesh J. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med. 350(14), 1387-1397 (2004).
26. Ridker PM, Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham risk scores. Circulation 109, 1955-1959 (2004).
27. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N. Engl. J. Med. 359 (18), 1897-1908 (2008).
28. Pepys MB, Hirschfield GM, Tennent GA et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 440, 1217-1221 (2006).
29. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing Type 2 diabetes mellitus. JAMA 286(3), 327-334 (2001).
30. Lopez-Garcia E. Consumption of trans fatty acids is related to plasma biomarkers of inflammation and endothelial dysfunction. J. Nutr. 135(3), 562-566 (2005).
31. Klebanoffl SJ. Myeloperoxidase: friend and foe. J. Leukoc. Biol. 77, 598-625 (2005).
32. Sugiyama S, Okada Y, Sukhova GK, Virmani R, Heinecke JW, Libby P. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol. 158(3), 879-891 (2001).
33. Daugherty A, Dunn JL, Rateri DL, Heinecke JW. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J. Clin. Invest. 94(1), 437-444 (1994).
34. Brennan ML, Anderson MM, Shih DM et al. Increased atherosclerosis in myeloperoxidase-deficient mice. J. Clin. Invest. 107, 419-430 (2001).
35. Hansson M, Olsson I, Nauseef WM. Biosynthesis, processing, and sorting of human myeloperoxidase. Arch. Biochem. Biophys. 445(2), 214-224 (2006).
36. Zheng L, Nukuna B, Brennan ML et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J. Clin. Invest. 114(4), 529-541 (2004).
37. Brennan M-L, Penn MS, Van Lente F et al. Prognostic value of myeloperoxidase in patients with chest pain. N. Engl. J. Med. 349, 1595-1604 (2003).
38. Baldus S, Heeschen C, Meinertz T et al.; CAPTURE investigators. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 108(12), 1440-1445 (2003).
39. Meuwese MC, Stroes ES, Hazen SL et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population study. J. Am. Coll. Cardiol. 50, 159-165 (2007).
40. Mocatta TJ, Pilbrow AP, Cameron VA et al. Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction. J. Am. Coll. Cardiol. 49(20), 1993-2000 (2007).
41. Garza CA, Montori VM, McConnell JP et al. Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. Mayo Clin. Proc. 82, 159-165 (2007).
42. Corson MA, Jones PH, Davidson MH. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am. J. Cardiol. 101(12A), 41F-50F (2008).
43. Ali M, Madjid M. Lipoprotein-associated phospholipase A2: a cardiovascular risk predictor and a potential therapeutic target. Future Cardiol. 5(2), 159-173 (2009).
44. Kolodgie FD, Burke AP, Skorija KS et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 26, 2523-2529 (2006).
45. Lavi S, McConnell JP, Rihal CS et al. Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation 115, 2715-2721 (2007).
46. Mannheim D, Herrmann J, Versari D et al. Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaque. Stroke 39, 1445-1448 (2008).
47. Vickers, KC, Maguire CT, Wolfert R et al. Relationship of lipoprotein-associated phospholipase A 2 and oxidized low density lipoprotein in carotid atherosclerosis. J. Lipid Res. 50, 1735-1743 (2009).
48. Macphee CH, Moores KE, Boyd HF et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem. J. 338, 479-487 (1999).
49. Safaya R, Chai H, Kougias P et al. Effect of lysophosphatidylcholine on vasomotor functions of porcine coronary arteries. J. Surg. Res. 126(2), 182-188 (2005).
50. Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler. Thromb. Vasc. Biol. 25, 923-931 (2005).
51. Tuczu EM, Kapadia SR, Tutar E et al. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound. Circulation 103, 2705-2710 (2001).
52. Wassertheil-Smoller S, Kooperberg C, McGinn AP et al. Lipoprotein-associated phospholipase A2, hormone use, and the risk of ischemic stroke in postmenopausal women. Hypertension 51(4), 1115-1122 (2008).
53. Sabatine MS, Morrow DA, O'Donoghue M et al.; PEACE investigators. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 27, 2463-2469 (2007).
54. Elkind MS, Tai W, Coates K, Paik MC, Sacco RL. High- sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch. Intern. Med. 166, 2073-2080 (2006).
55. Brilakis ES, McConnell JP, Lennon RJ, Elesber AA, Meyer JG, Berger PB. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur. Heart J. 26, 137-144 (2005).
56. Melander O, Newton-Cheh C, Almgren P et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA 302(1), 49-57 (2009).
57. Cook N. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 115, 928-935 (2007).
58. Nambi V, Hoogeveen RC, Chambliss L et al. Lipoprotein associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the atherosclerosis risk in communities (ARIC) study. Stroke 40, 376-381 (2009).
59. Davidson MH, Alberts MJ, Anderson JL et al. Consensus panel recommendation for incorporating Lp-PLA2 testing into cardiovascular disease risk assessment guidelines. Am. J. Cardiol. 101(Suppl.), 51F-57F (2008).
60. Winkler K, Hoffman MM, Winkelmann BR et al. Lipoprotein- associated phospholipase A2 predicts 5-year mortality independently of established risk factors and adds prognostic information in patients with low and medium high-sensitivity C-reactive protein (the Ludwigshafen Risk and Cardiovascular Health Study). Clin. Chem. 53, 1440-1447 (2007).
61. Gerber Y, McConnell JP, Jaffe AS, Weston SA, Killian JM, Roger VL. Lipoprotein-associated phospholipase A2 and prognosis after myocardial infarction in the community. Arterioscler. Thromb. Vasc. Biol. 26, 2517-2522 (2006).
62. Lanman RB, Wolfert RL, Fleming JK et al. Lipoprotein-associated phospholipase A2: review and recommendation of a clinical cut point for adults. Prev. Card. 9(3), 138-143 (2006).
63. Rosenson RS. Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome. Am Heart J. 155(3), 499.e9-e16 (2008).
64. Kuvin JT, Dave DM, Sliney KA et al. Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am. J. Cardiol. 98, 743-745 (2006).
65. Saougos VG, Tambaki AP, Kalogirou M et al. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler. Thromb. Vasc. Biol. 27, 2236-2243 (2007).
66. Aird WC, Daugherty A, Davis GE et al. Lipoprotein subfraction responses differentially predict changes in lipoprotein-associated phospholipase A2 during prescription omega-3 therapy. Arterioscler. Thromb. Vasc. Biol. e94 (2007) (Abstract P328).
67. Albert MA, Glynn RJ, Wolfert RL, Ridker PM. The effect of statin therapy on lipoprotein associated phospholipase A2 levels. Atherosclerosis 182(1), 193-198 (2005).
68. Wilensky RL, Shi Y, Mohler ER et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat. Med. 14(10), 1059-1066 (2008).
69. McCullough PA. Darapladib and atherosclerotic plaque: should lipoprotein-associated phospholipase A2 be a therapeutic target? Curr. Atheroscler. Rep. 11(5), 334-337 (2009).
70. Shi Y, Zalewski A, Macphee C, Dawson M. Selective inhibition of lipoprotein-associated phospholipase A2 attenuates markers of plaque vulnerability in humans. Circulation 116(Suppl.), II-108 (2007).
71. Mohler ER, Ballantyne CM, Davidson MH et al.; Darapladib investigators. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J. Am. Coll. Cardiol. 51(17), 1632-1641 (2008).
72. Serruys PW, García-García HM, Buszman P et al.; Integrated Biomarker and Imaging Study-2 investigators. Effects of the direct lipoprotein-associated phospholipase A2 inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 118(11), 1172-1182 (2008).
73. Riley RF, Corson MA. Darapladib, a reversible lipoprotein-associated phospholipase A2 inhibitor, for the oral treatment of atherosclerosis and coronary artery disease. IDrugs 12(10), 648-655 (2009).
74. McCullough PA, Lepor NE. Lipids, biomarkers, and noninvasive imaging of atherosclerotic disease activity in clinical trials. Rev. Cardiovasc. Med. 9(2), 142-149 (2008).
75. Lele S, Shah S, McCullough PA, Rajapurkar M. Serum catalytic iron as a novel biomarker in acute coronary syndromes. EuroIntervention 5(3), 336-342 (2009).
76. Lowe GD, Pepys MB. C-reactive protein and cardiovascular disease: weighing the evidence. Curr. Atheroscler. Rep. 8(5), 421-428 (2006).
77. Koenig W, Khuseyinova N, Löwel H, Trischler G, Meisinger C. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany (MONICA study). Circulation 110(14), 1903-1908 (2004).